Merck KGaA to Develop AI-driven Support Model for Rare Tumors, Partner with Nvidia, MSFT

 

• Collaboration to explore how AI-facilitated technology can help make patient support programs more individualized, responsive and continuously available to people living with rare tumors
• Collaboration brings together clinical and pharmaceutical expertise, digital health product development, and enterprise AI services
• Merck aims to bring the model to patients with desmoid tumors and neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN)
  
  
  Merck, a leading science and technology company, today announced a collaboration with NVIDIA Corporation (Santa Clara, California, USA), Microsoft Corporation (Redmond, Washington, USA) and Dawn Health A/S (Copenhagen, Denmark) to build an innovative model for Patient Support Programs (PSPs). The four-way collaboration brings together pharmaceutical and clinical expertise, enterprise technology, AI services and digital health product design, with the shared goal of making specialist-level support more individualized, responsive and continuously available to patients.

https://www.businesswire.com/news/home/20261020304233/en/Merck-Collaborates-with-NVIDIA-Microsoft-and-Dawn-Health-to-Develop-Novel-Support-Model-for-People-Living-with-Rare-Tumors